Vanguard Group Inc Eq Rx, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $1.24 Million - $1.72 Million	745,558 Added 2.29%	33,264,378 $73.8 Million
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $1.01 Million - $1.23 Million	625,164 Added 1.96%	32,518,820 $60.5 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $10.7 Million - $16.8 Million	5,940,915 Added 22.89%	31,893,656 $61.9 Million
Q4 2022 Feb 10, 2023	BUY	$2.05 - $5.5 $7.73 Million - $20.7 Million	3,772,035 Added 17.01%	25,952,741 $63.8 Million
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $16.9 Million - $108 Million	17,951,884 Added 424.51%	22,180,706 $110 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $4.13 Million - $7.35 Million	1,291,528 Added 43.97%	4,228,822 $19.8 Million
Q1 2022 May 13, 2022	BUY	$2.8 - $7.39 $8.22 Million - $21.7 Million	2,937,294 New	2,937,294 $12.1 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.